1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Krsnaa Diagnostics Limited

Krsnaa Diagnostics Limited

KRSNAA.BO
Krsnaa Diagnostics LimitedIN flagBombay Stock Exchange
551.25
INR
-10.45
- -
17.92BMarket Cap
Krsnaa Diagnostics Limited
KRSNAA.BO
(Bombay Stock Exchange)

Recent

price

551.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
66.64
82.31
126.27
152.44
155.15
195.18
222.15
- -
238.69
Revenue per Share
-18.49
-35.66
58.9
22.89
19.78
17.9
24.04
- -
31.33
Basic EPS, GAAP
-13.22
-12.4
11.38
-1.27
-20.72
-53.41
-12.17
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
2.5
2.72
2.5
- -
- -
Dividend per Share
-34.73
-70.39
-11.06
14.35
30.96
46.18
67.1
- -
5.01
Book Value per Share
-32.1
-68
-3.74
228.3
234.38
254.32
272.54
- -
301.32
Tangible Book Value per Share
31
31
31
30
31
32
32
- -
32
Basic Weighted Avg Shares
2,092
2,584
3,965
4,554
4,871
6,196
7,172
7,728
7,728
Sales/Revenue/Turnover
15.43
11.77
14.35
19.83
14.21
11.26
14.2
15.71
15.71
Operating Margin (%)
256
323
374
414
538
745
883
905
905
Depreciation Expense
-581
-1,120
1,849
684
621
568
776
1,014
1,014
Net Income, GAAP
- -
- -
37.41
20.95
22.56
18.81
24.42
22.2
22.2
Effective Tax Rate (%)
-27.75
-43.32
46.65
15.02
12.75
9.17
10.82
13.13
13.13
Profit Margin (%)
153
328
643
2,131
1,237
1,397
1,091
4,631
4,631
Working Capital
921
1,227
1,680
331
243
419
472
4,683
4,683
LT Debt
-849
-1,970
2,319
6,844
7,387
8,098
8,828
9,804
9,804
Total Equity
- -
- -
14.59
12.1
7.21
6.55
7.51
7.26
7.26
Return on Invested Capital (%)
- -
- -
86.3
31.23
62.84
31.31
26.49
26.41
26.41
Return on Capital (%)
- -
- -
- -
- -
88.68
46.63
42.73
87.13
87.12
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
1,968
- -
660
LT Borrowings
538
- -
4,371
LT Finance Leases
351
- -
311
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
- -
32
Market Capitalization
24,486
23,298
16,871

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
5,767
- -
7,383
Cash, Cash Equivalents & STI
1,597
- -
3,920
Accounts Receivable, Net
3,583
- -
2,955
Inventories
315
- -
267
Total Current Liabilities
4,075
- -
2,752
Payables & Accruals
- -
- -
- -
ST Debt
1,968
- -
660
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
46.56%
11.06%
Free Cash Flow
- -
336.26%
93.79%
Net Income, GAAP
- -
-2.69%
30.7%
Sales/Revenue/Turnover
- -
14.5%
7.75%
Total Cash Common Dividend
- -
- -
10.52%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,396
1,554
1,583
1,663
6,196
2025
1,702
1,863
1,745
1,861
7,172
2026
1,930
2,060
1,812
1,926
7,728

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.66
3.35
4.09
- -
17.9
2025
5.55
6.07
6.01
6.4
24.04
2026
6.35
7.38
4.72
12.86
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.72
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
- -
Similar Companies
Eurofins-Cerep S.A. (ALECR.PA)
Applied DNA Sciences, Inc. (APDN)
PT Diagnos Laboratorium Utama Tbk (DGNS.JK)
Integrated Diagnostics Holdings plc (IDHC.L)
Enzo Biochem, Inc. (ENZ)
Bangkok Genomics Innovation Public Company Limited (BKGI.BK)
Business
Krsnaa Diagnostics Limited provides technology-enabled diagnostic services, including radiology imaging such as MRI, CT scans, X-rays, mammography, ultrasound, bone densitometry and color Doppler; pathology and clinical laboratory testing encompassing biochemistry, haematology, clinical pathology, histopathology, cytopathology, microbiology, serology and immunology with 2,544 pathological tests; and teleradiology reporting services through its NABH-accredited hub in Pune. The company operates an extensive network of over 5,156 diagnostic centres, including 178 CT/MRI centres, 300+ pathology labs, 3,139 collection centres and 1,434 teleradiology centres, across 18 states and union territories in India, primarily in non-metro and lower-tier cities, serving public and private hospitals, medical colleges and community health centres under public-private partnership models. Founded in 2010 and headquartered in Pune, Maharashtra, Krsnaa Diagnostics focuses on an asset-light expansion strategy with business-to-government partnerships and targets underserved regions. In late 2024, the company acquired a 23.53% stake in Apulki Healthcare, India's first PPP dedicated to cancer and cardiac care hospitals, to integrate specialized oncology and cardiology diagnostics for hospital and retail patients in urban areas; it plans to add over 200 centres in the next two years, alongside AI and automation enhancements in radiology and pathology to drive over 20% revenue growth. Recent operational expansions include 25 labs and over 500 collection centres as of November 2025, with Q2 FY2026 revenue up 11% year-on-year to Rs 2,060 million and net profit rising 49.73% in the December 2024 quarter.